7 research outputs found
Extraction and purification of queen venom and worker venom protein (Sol i II)
No full textThe author has granted permission for their work to be available to the general public.Solenopsis Invicta is a serious invasive species which causes anaphylaxis (venom allergic reactions) with its painful sting. In 1988, Hoffman, et al. isolated the four different types of proteins in fire ant venom and noted that these proteins have significant allergenic activity towards immunoglobulin E (Ig E). Among these four proteins, two of them were characterized. This research project focused on expression and purification of one of the uncharacterized proteins, (Sol i II) found in both Worker Venom and Queen Venom variants. My research started with the production of Queen and Worker synthetic Sol i II genes, optimized for expression in E. coli by assembly PCR and then cloned into BL-21 cells for protein expression. However, when the protein was expressed in these cells, it also contains endotoxin in the end product hindering future research work with this protein. To overcome this I am attempting to transform these Sol i II genes into Bacillus megaterium to produce an endotoxin-free final product.Integrative Biolog
Perception Based Decision Support System for Handwriting Behaviour Analysis
No full textAbstractHandwritten text is potentially the most powerful and conventional means of personal authentication in Human Computer Interaction, with applications to be found in document analysis, deception detection, banking and many other areas. Handwriting is a complex perceptual motor task generating linguistic information. Characters reflect shape distinction needed to perceive different phonetic information of words. In this paper, we have tried to emphasize the role of perception and cognition in identifying unique characteristics of handwriting of any person to screen out deceptive and true statements as a computational model in the areas of Pattern Recognition and Human Computer Interaction. The paper reports the prototype development of a decision support system based on handwriting behavior analysis
Land and Dispossession
No full textIn this postscript the author revisits the place of land in the capitalist development process generally and in late developers such as India. Primitive accumulation has been the modus operandi for reducing surplus labor, by separating the peasants from their land, and a source of agrarian dynamism, leading to the rise of a wage-dependent proletariat. However, in India this process has been shown to be incomplete. In the absence of a classical capitalist transition India’s transformation remains muted with the formation of a persistent petty commodity producer sector. This concluding set of remarks reflects broadly on the nature of impending politics such as the ability of the state to politically manage those that are outside the formal orbits of capital or when jobs disappear and self-employment become routine in an expanding economy but without dissolving the PCP. Instead, when land and livelihoods are contested and dispossession becomes inevitable.</p
Fear of cancer recurrence and change in hair cortisol concentrations in partners of breast cancer survivors
No full textThis article was originally published in Journal of Cancer Survivorship. The version of record is available at: https://doi.org/10.1007/s11764-024-01631-1.
© The Author(s) 2024.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This research was featured in UDaily on 12/12/2024 at: https://www.udel.edu/udaily/2024/december/increased-cortisol-in-partners-of-breast-cancer-survivors-jean-philippe-laurenceau/Purpose
Partners of breast cancer (BC) survivors report high rates of psychological distress including fear of cancer recurrence (FCR). Research suggests that partners may have poorer physical health outcomes than the general population, but little research has examined the physiological biomarkers by which distress may impact partner health outcomes. The current study examined the associations between FCR and changes in hair cortisol among BC partners.
Methods
Male partners (N = 73) of early-stage BC survivors provided hair samples during two visits, one after completion of survivors’ adjuvant treatment (T1) and again 6 months later (T2). Two subscales from the Fear of Cancer Recurrence Inventory and one subscale from the Concerns about Recurrence Scale comprised a latent FCR factor at T1. A latent change score model was used to examine change in cortisol as a function of FCR.
Results
Partners were on average 59.65 years of age (SD = 10.53) and non-Hispanic White (83%). Latent FCR at T1 was positively associated (b = 0.08, SE = 0.03, p = .004, standardized β = .45) with change in latent hair cortisol from T1 to T2.
Conclusions
Results indicated that greater FCR was associated with increases in hair cortisol in the months following adjuvant treatment. This is one of the first studies to examine the physiological correlates of FCR that may impact health outcomes in BC partners.
Implications for Cancer Survivors.
Findings highlight the need for further research into the relationship between FCR and its physiological consequences. Interventions to address partner FCR are needed and may aid in improving downstream physical health outcomes.This study was partially supported by a grant funded by the National Cancer Institute (R21CA171921; PI: Laurenceau)
Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series
No full textArticle full text
The full text of this article can
be found here.
Provide enhanced content for this
article
If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact [email protected].
The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as ‘peer reviewed’ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.
Other enhanced features include,
but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides</p
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
No full textInternational audienceBACKGROUND:Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.METHODS:This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.FINDINGS:Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043).INTERPRETATION:Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding
